×

Biomarkers and targets for diagnosis prognosis and management of prostate disease

  • US 6,171,796 B1
  • Filed: 08/03/1999
  • Issued: 01/09/2001
  • Est. Priority Date: 01/21/1998
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of diagnosing metastatic prostate cancer in a subject, comprising the steps of:

  • (a) obtaining one or more test samples from prostate tissue or serum or both of said subject; and

    (b) detecting a decrease in the amount of polypeptide expressed from a metastatic prostate cancer marker gene selected from prostate-specific transglutaminase, cytokeratin 15, or semenogelin II or a combination thereof in said test samples;

    wherein a decrease in the expression of prostate-specific transglutaminase or cytokeratin 15 polypeptide in a test sample from prostate tissue or of semenogelin II polypeptide in a test sample from serum is diagnostic for metastatic prostate cancer.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×